article thumbnail

Supercharging AI-drug discovery with strategic multiomic biobanksĀ 

Drug Discovery World

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Not all biobanks are created equal Biobanks provide a treasure trove of clinical data for exploration with AI tools. But the utility of biobanks varies.

article thumbnail

When You Got Your Period May Impact Dementia Risk, Study Finds

AuroBlog - Aurous Healthcare Clinical Trials blog

The analysis included health information from 273,260 female participants in the United Kingdom Biobank, and the findings suggest that those who start their period younger and go […]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Overcoming the Challenges of Sample Tracking in Clinical Trials with Blockchain Technology

Crucial Data Soutions

Itā€™s 2021 and sharpies are still being used to write on bio sample tubes in most clinical trialsā€¦. As most people would agree, one core tenant of a well-run clinical trial is accurately collecting, handling and analyzing bio samples from subjects during the study. Background.

article thumbnail

University of Melbourne reveals design of new infectious disease institute

Pharmaceutical Technology

The new AIID building will include a human infection challenge unit, high-containment facilities, a robotic biobanking facility, interview rooms, dry laboratories and spaces for community engagement and co-design work. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

article thumbnail

What are the key trends in genomics and precision medicine for 2024?

Drug Discovery World

Utilising diverse data in clinical trials for drug discovery: Key speakers from pharma and industry discussed the integration of diverse data in clinical trials, emphasising its role in accelerating drug discovery processes for more effective and personalised treatments.

Genome 57
article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ā€˜recontact by genotypeā€™ studies that the Resilience Project would have liked to do. Giving participants something in return.

article thumbnail

EMA unveils first projects as data partners join DARWIN EU project

pharmaphorum

More than two years on, the EU medicines regulator has now selected the first set of data partners to collaborate with DARWIN EU, which focuses on real-world evidence collected on a patient’s health status or delivery of healthcare from a variety of sources, other than conventional clinical trials.